tirzepatide percent weight loss Efficacy and safety of for treatment of overweight or obesity. A systematic review and meta-analysis The results are finally in

To improve or achieve remission of some obesity-related complications and lower risk for cardiovascular events, individuals with a BMI of 35 kg/m 2 may need to lose more weight (1025%)

GLP-1 RAs help break this pathogenic cycle by fostering a mucosal environment that supports structural health

Tardito S, Bassanetti I, Bignardi C, Elviri L, Tegoni M, Mucchino C, et al

Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus treatment The most common side effects are gastrointestinal, including nausea, diarrhoea, vomiting, and constipation Peripheral oedema is not listed as an adverse reaction in the UK Summary of Product Characteristics Individual responses vary and any unexplained swelling or weight gain warrants medical assessment Regular monitoring includes HbA1c, renal function, body weight, and blood pressure during treatment Table of Contents Understanding Mounjaro and Its Mechanism of Action Does Mounjaro Cause Fluid Retention

Anyone facing surgery or endoscopy should tell their doctor, as the dose may need to be paused